These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 17447061)

  • 1. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
    Souvatzoglou M; Grosu AL; Röper B; Krause BJ; Beck R; Reischl G; Picchio M; Machulla HJ; Wester HJ; Piert M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1566-75. PubMed ID: 17447061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
    Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
    Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
    Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
    Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
    Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
    Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
    J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
    Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
    Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
    J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three
    Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
    Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.
    Iqbal R; Kramer GM; Verwer EE; Huisman MC; de Langen AJ; Bahce I; van Velden FH; Windhorst AD; Lammertsma AA; Hoekstra OS; Boellaard R
    J Nucl Med; 2016 Apr; 57(4):530-5. PubMed ID: 26659349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy.
    Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y
    Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer.
    Havelund BM; Holdgaard PC; Rafaelsen SR; Mortensen LS; Theil J; Bender D; Pløen J; Spindler KL; Jakobsen A
    Nucl Med Commun; 2013 Feb; 34(2):155-61. PubMed ID: 23196674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of [
    Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
    Acta Oncol; 2017 Apr; 56(4):516-524. PubMed ID: 28358668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First Evaluation of PET-Based Human Biodistribution and Dosimetry of
    Savi A; Incerti E; Fallanca F; Bettinardi V; Rossetti F; Monterisi C; Compierchio A; Negri G; Zannini P; Gianolli L; Picchio M
    J Nucl Med; 2017 Aug; 58(8):1224-1229. PubMed ID: 28209906
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
    Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors.
    Shi K; Souvatzoglou M; Astner ST; Vaupel P; Nüsslin F; Wilkens JJ; Ziegler SI
    J Nucl Med; 2010 Sep; 51(9):1386-94. PubMed ID: 20720045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer.
    Schuetz M; Schmid MP; Pötter R; Kommata S; Georg D; Lukic D; Dudczak R; Kletter K; Dimopoulos J; Karanikas G; Bachtiary B
    Acta Oncol; 2010 Oct; 49(7):941-7. PubMed ID: 20831481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.